Today’s change applies to affected grantees
Johnson & Johnson Health Care Systems announced the designation policy September 4, 2026. Its notice sets September 15 for hospitals and November 3 for affected grantee covered entities. For products listed in the notice, the grantee generally may designate one active contract pharmacy dispensing site within 40 miles of its site. A separate specialty pharmacy designation is available for specified pulmonary arterial hypertension drugs in the manufacturer’s limited distribution network.1
The notice excludes AIDS Drug Assistance Programs and says applicable state exceptions are communicated separately. October 20 was the designation deadline for activation by November 3. For designations made beginning October 21, the manufacturer instructs entities to allow ten business days for activation.12
Check the dispensing site before replenishment
The company’s separate claims submission policy ties conforming claims to an eligible location active on the date of service. It sets a general 45-day submission period and allows 60 days for specified products. These are manufacturer pricing conditions.3
Chad’s analysis: Compare the actual dispensing site, its registration and designation status, and the product list before replenishment. Assign someone to resolve a mismatch with the covered entity and wholesaler before assuming discounted acquisition. Review any state exception that applies to the entity separately and plan how to keep therapy available while an order or designation is resolved.
Source notes
- Johnson & Johnson Health Care Sys. Inc., Notice to 340B Covered Entities Regarding 340B Contract Pharmacy Designations, at 1–2 (Sept. 4, 2026).
- Id. at 5–6, FAQ 15 & attachment A.
- Johnson & Johnson Health Care Sys. Inc., Notice to Covered Entities Regarding 340B Claims Data Submission Policy, at 2 (Sept. 4, 2026).